FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, particularly to humanised antibody, which specifically binds to LIV-1, as well as a nucleic acid coding mature variable heavy chain region and to nucleic acid coding mature variable light chain region of said antibody. Also disclosed is a conjugate of said humanised antibody with cytotoxic or cytostatic agent for treatment or preventive treatment of cancer, associated with expression of LIV-1. Invention also relates to a method of treatment or preventive treatment of a patient, having cancer or at risk of cancer associated with expression of LIV-1, as well as to a pharmaceutical composition for treatment or preventive treatment of cancer associated with expression of LIV-1.
EFFECT: invention provides effective treatment or preventive treatment of cancer associated with expression of LIV-1.
21 cl, 28 dwg, 8 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2736720C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| ANTI-MUC1 DRUG CONJUGATE | 2019 |
|
RU2804703C2 |
| ANTIBODIES AND IMMUNOCONJUGATES AND THEIR APPLICATIONS | 2007 |
|
RU2639543C9 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
| ANTI-SEZ6 ANTIBODIES AND METHODS FOR USING THEM | 2013 |
|
RU2691698C2 |
| ANTIBODIES AND IMMUNOCONJUGATES RENDERED BY IMMUNO-POSITRON EMISSION TOMOGRAPHY, METHODS OF APPLICATION | 2011 |
|
RU2613886C2 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
